Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
14 Juni 2021 - 12:05PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia
or the Company) announced today the appointment of Dr. Brinda
Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors
effective June 14, 2021. Dr. Balakrishnan is Group Vice President,
Corporate and Business Development of BioMarin Pharmaceutical Inc.
(“BioMarin”), a global biotechnology company that develops and
commercializes innovative therapies for patients with serious and
life-threatening rare disorders. At BioMarin, Dr. Balakrishnan
leads initiatives on corporate strategy, mergers and acquisitions,
partnering and licensing.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210614005185/en/
Dr. Brinda Balakrishnan, newly appointed
Director to the Aurinia Pharmaceuticals Board. (Photo: Business
Wire)
“On behalf of the entire Company, it is an honor to welcome Dr.
Balakrishnan to Aurinia’s Board of Directors,” commented Peter
Greenleaf, President and Chief Executive Officer of Aurinia. “With
her rich experience in medicine, biotech business development and
the rare disease space, we are eager to leverage her input and
insights as we continue in our mission to support and better treat
people suffering with rare, autoimmune diseases, including lupus
nephritis.”
“I am delighted to join the Board of Directors of Aurinia,” said
Dr. Balakrishnan. “The Company is at an exciting moment in its
evolution, and I look forward to working with the Board and
management team as Aurinia continues on its mission to serve people
suffering from debilitating autoimmune diseases.”
Dr. Balakrishnan has been at BioMarin since 2016. Prior to
joining BioMarin, Dr. Balakrishnan was the co-founder and Vice
President of corporate strategy and product development at Vision
Medicines, Inc., a start-up focused on developing treatments for
rare ophthalmic diseases. Before Vision Medicines, she spent two
years as a consultant at McKinsey & Company in the healthcare
practice, serving clients across small biotech, large pharma, and
healthcare provider groups on topics related to corporate strategy,
corporate and business development, and operations. Prior to
McKinsey, Dr. Balakrishnan was in business development at
Genzyme.
Dr. Balakrishnan earned a B.S. degree from the Massachusetts
Institute of Technology (MIT) in chemical engineering and a Ph.D.
from MIT in biomedical engineering and chemical engineering. She
also earned her M.D. degree from Harvard Medical School and
conducted her medical training in internal medicine at Beth Israel
Deaconess Medical Center in Boston, a Harvard hospital.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations that are impacted by serious diseases with a high unmet
medical need. The Company’s head office is in Victoria, British
Columbia, its U.S. commercial hub is in Rockville, Maryland, and
the Company focuses its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210614005185/en/
Investors: Glenn Schulman, PharmD, MPH Investor Relations
& Corporate Communications, Aurinia
gschulman@auriniapharma.com
Media: Dana Lynch Corporate Communications, Aurinia
dlynch@auriniapharma.com